Markets:

Overview

News

Currencies

International

Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

32.13 +1.85 (+6.11%)

Streaming Delayed Price Updated: 1:31 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

June 20, 2022

From Edgewise Therapeutics

Via Business Wire

New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

June 16, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at Upcoming Investor Conferences

May 31, 2022

From Edgewise Therapeutics

Via Business Wire

Recap: Edgewise Therapeutics Q1 Earnings ↗

May 11, 2022

Edgewise Therapeutics (NASDAQ:EWTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

March 25, 2022

On Friday, 166 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Analyst Ratings for Edgewise Therapeutics ↗

May 12, 2022

Over the past 3 months, 4 analysts have published their opinion on Edgewise Therapeutics (NASDAQ:EWTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Edgewise Therapeutics Reports First Quarter 2022 Financial Results

May 11, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at Upcoming Investor Conferences

May 03, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling

April 14, 2022

From Edgewise Therapeutics

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

March 24, 2022

On Thursday, 112 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Stanley Black & Decker (NYSE:SWK) was the largest firm by market...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 23, 2022

On Wednesday, 63 companies set new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗

March 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

February 24, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16

February 02, 2022

From Edgewise Therapeutics

Via Business Wire

52 Biggest Movers From Friday ↗

January 31, 2022

Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 28, 2022

Gainers Provention Bio (NASDAQ:PRVB) stoc...

Via Benzinga

Stocks Move Higher Midday, Still Pacing for Weekly Losses ↗

January 28, 2022

Stocks are continuing their rollercoaster pattern midday, as Wall Street attempts to lift itself out of the worst selloff since March 2020.

Via Talk Markets

33 Stocks Moving In Friday's Mid-Day Session ↗

January 28, 2022

Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF...

Via Benzinga

50 Biggest Movers From Yesterday ↗

January 06, 2022

Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead...

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Down 300 Points; Annexon Shares Plunge ↗

January 05, 2022

Toward the end of trading Wednesday, the Dow traded up 0.24% to 36,711.36 while the NASDAQ fell 1.93% to 15,321.38. The S&P also fell, dropping 0.80% to 4,755.18. The U.S. has...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 05, 2022

Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 70.4% to $2.3 during Wednesday's regular session. Trading volume for this security as of 12:31 EST is...

Via Benzinga

34 Stocks Moving In Wednesday's Mid-Day Session ↗

January 05, 2022

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage...

Via Benzinga

Edgewise Therapeutics Shares Jump After Positive Data On Becker Muscular Dystrophy Study ↗

January 05, 2022

Edgewise Therapeutics Inc (NASDAQ: EWTX) posted positive topline results from Phase 1b trial of EDG-5506, designed to protect injury-susceptible fast skeletal...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets ↗

January 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...

Via Benzinga

Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)

January 05, 2022

From Edgewise Therapeutics

Via Business Wire

The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week.

Via Talk Markets

The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration...

Via Benzinga

Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study

December 15, 2021

From Edgewise Therapeutics

Via Business Wire

63 Biggest Movers From Friday ↗

December 20, 2021

Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.